split-banner-image

TAILORx

Closed

ANZ 0901/PACCT-1: TAILORx

BCT Study Chair:

Joanna Dewar

A phase III, multicentre, multinational, randomised trial of adjuvant chemotherapy plus hormone treatment versus adjuvant hormone treatment alone for patients with previously resected, axillary node-negative, invasive breast cancer with various levels of risk for recurrence.

international

10248

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

25

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

16

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

TAILORX PUBLICATIONS

2024

Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials.

Pan H, Gray R, on behalf of the EBCTCG. Journal of Clinical Oncology. 2024; 32:5s(SABCS 2024), [Abstract Number SESS-1911; GS2-09], Abstract

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.

Early Breast Cancer Trialists’ Collaborative Group. The Lancet. 2024; 4041407-18, epub 12 October 2024, E-pub

2022

Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates.

Sparano J, Gray RJ, Makower D, Albain KS, Hayes DF, Geyer C, Dees E, Goetz MP, Olson Jr JA, Lively TG, Badve S, Saphner T, Wagner LI, Whelan T, Kaklamani V, Sledge G. San Antonio Breast Cancer Symposium. 2022; Abstract# GS1-05, Abstract

Racial/ethnic disparities in locoregional recurrence in hormone-receptor positive node negative breast cancer patients enrolled in the TAILORx trial.

Kantor O, King AT, Freedman AR, Mayer LE, MacGregor MC , Korde AL, Sparano AJ, Mittendorf AE. Journal of Clinical Oncology. 2022; 40(16 suppl):ASCO Abstract #515, Abstract

2021

Customising Local and Systemic Therapies for women with Early Breast Cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

Burstein HJ, Curigliano G, Thurlimann B, Weber WP, Poortmans P, Regan M, Senn HJ, Winer EP, Gnant M, Panelists of the St Gallen Consensus Conference. Annals of Oncology. 2021; (in press)DOI:https://doi.org/10.1016/j.annonc.2021.06.023., Journal

2019

Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study.

Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J. SABCS 2019; GS4-03, Presentation

LOAD MORE

Institutions